Why Is Rosacea Considered to Be an Inflammatory Disorder?
The Primary Role, Clinical Relevance, and Therapeutic Correlations of Abnormal Innate Immune Response in Rosacea-Prone Skin

June 2012 | Volume 11 | Issue 6 | Original Article | 694 | Copyright © June 2012


James Q. Del Rosso DO FAOCD,a Richard L. Gallo MD PhD,b Leon Kircik MD,c Diane Thiboutot MD,d Hilary E. Baldwin MD,e and David Cohen MDf

aValley Hospital Medical Center, Las Vegas, NV; Touro University College of Osteopathic Medicine, Henderson, NV; and Las Vegas Skin and Cancer Clinics, Las Vegas, NV and Henderson, NV bUniversity of California San Diego, San Diego, CA cPhysicians Skin Care, PLLC, Louisville, KY; Mount Sinai Medical Center, New York, NY and Indiana University School of Medicine, Indianapolis, IN dPennsylvania State University College of Medicine, Hershey, PA eDepartment of Dermatology, SUNY Downstate, Brooklyn, NY fNew York University School of Medicine, Department of Dermatology, New York, NY

Keyword: Rosacea 

  1. Subramanyan K. Role of mild cleansing in the management of patient skin. Dermatol Ther. 2004;17(4 suppl):26-34.
  2. Torok HM. Rosacea skin care. Cutis. 2000;66(4 Suppl):14-16.
  3. Marks R. The enigma of rosacea. J Dermatol Treat. 2007;18:326-328.
  4. Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci. 2009;55(2):77-81.
  5. Fleischer AB. Inflammation in rosacea and acne: implications for patient care. J Drugs Dermatol. 2011;10:614-620.
  6. Guzman-Sanchez DA, Ishiuji Y, et al. Enhanced skin blood flow and sensitivity to noxious heat stimuli in papulopustular rosacea. J Am Acad Dermatol. 2007;57:800-805.
  7. Oztas MO, Balk M, Ogus E, et al. The role of free radicals in the aetiopathogenesis of rosacea. Clin Exp Dermatol. 2003;28:188-192.
  8. Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skin innate immunity. J Invest Dermatol. 2011;15:53-62.
  9. Bevins CL, Liu FT. Rosacea: skin innate immunity gone awry? Nat Med. 2007;13(8):904-906.
  10. Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol. 2011;131:688-697.
  11. Rosina P, Zamperetti M, Giovannini A, et al. Videocapillaroscopic alterations in erythematotelangiectatic rosacea. J Am Acad Dermatol. 2006;54:100-104.
  12. De Y, Chen Q, Schmidt AP, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL-1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med. 2000;192:1069-1074.
  13. Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003;111:1665-72.
  14. Park HJ, Cho DH, Kim HJ, et al. Collagen synthesis is suppressed in dermal fibroblasts by the human antimicrobial peptide LL-37. J Invest Dermatol. 2009;129:843-50.
  15. Aubdool AA, Brain SD. Neurovascular aspects of skin neurogenic inflammation.J Invest Dermatol. 2011;15:33-39.
  16. Del Rosso JQ. Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis. 2006;78:97-100.
  17. Martin DB, Gaspari AA. Toll-like receptors. In: Gaspari AA, Tyring SK, Eds. Clinical and Basic Immunology. Springer-Verlag, London, 2008, pp 67-84.
  18. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature. 2006;442:39-44.
  19. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin Dmediated human antimicrobial response. Science. 2006;311:1770-1773.
  20. Lundwall A, Brattsand M. Kallikrein-related peptidases. Cell Mol Life. 2008;65:2019-2038.
  21. Sotiropoulo G, Pampalakis G, Diamandis EP. Functional roles of human kallikrein-related peptidases. J Biol Chem. 2009;284:32989-32994.
  22. Lazaridou E, Giannopoulou C, Fotiadou C, et al. The potential role of microorganisms in the development of rosacea. J Dtsch Dermatol Ges. 2011;9:21-25.
  23. McAleer MA, Lacey N, Powell FC. The pathophysiology of rosacea. G Ital Dermatol Venereol. 2009;144:663-671.
  24. Bielenberg DR, Bucana CD, Sanchez R, et al. Molecular regulation ofUVBinduced cutaneous angiogenesis. J Invest Dermatol. 1998;111:864-872.
  25. Kanada KN, Nakatsuji T, Gallo RL. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Invest Dermatol. 2012 (accepted for publication).
  26. Dirschka T, Tronnier H, Folster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol. 2004;150:1136-1141.
  27. Draelos ZD. Treating beyond the histology of rosacea. Cutis. 2004;74(3 Suppl):28-31.
  28. Torok HM. Rosacea skin care. Cutis. 2000;66(4 Suppl):14-16.
  29. Elias PM. The skin barrier as an innate immune element. Semin Immunopath. 2007;29:3-14.
  30. Voegeli R, Rawlins AV, Doppler S, et al. Increased basal transepidermal water loss leads to elevation of some but not all stratum corneum serine proteases. Int J Cos Sci. 2008; 30:435-42.
  31. Del Rosso JQ, Levin J. The clinical relevance of maintaining the functional integrity of the stratum corneum in both healthy and disease-affected skin. J Clinical Aesthet Dermatol. 2011;91:22-42.
  32. Pelle MT, Crawford GH, James WD. Rosacea II: therapy. J Am Acad Dermatol. 2004;51:499-512.
  33. Del Rosso JQ. Medical treatment of rosacea with emphasis on topical therapies. Expert Opin Pharmacother. 2004;5:5-13.
  34. McClellan KJ, Noble S. Topical metronidazole: a review of its uses in rosacea. Am J Clin Dermatol. 2000;1:191-199.
  35. Liu RH, Smith MK, Basta SA, et al. Azelaic acid in the treatment of papulopustular rosacea: a systematic review of randomized controlled trials. Arch Dermatol. 2006;142:1047-1052.
  36. Odom R, Dahl M, Dover J, et al. Standard management options for rosacea, part 2: options according to rosacea subtype. Cutis. 2009;84:97-104.
  37. Kennedy Carney C, Cantrell W, Elewski BE. Rosacea: a review of current topical, systemic and light based therapies. G Ital Dermatol Venereol. 2009;144:673-688.
  38. Del Rosso JQ, Webster GW, Jackson M, et al. Two randomized phase II clinical trials evaluating anti-inflammatory dose doxycycline (40 mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56:791-801.
  39. Del Rosso JQ. Anti-inflammatory dose doxycycline in the treatment of rosacea. J Drugs Dermatol. 2009;8:664-668.
  40. Webster GF. An open-label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40 mg (30-mg immediate- release and 10-mg delayed-release beads). Cutis. 2010;86(5 Suppl):7-15.
  41. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. 1994;130:319-24.
  42. Park H, Del Rosso JQ. Use of oral isotretinoin in the management of rosacea. J Clin Aesthet Dermatol. 2011;4:54-61.
  43. Del Rosso JQ. Advances in understanding and managing rosacea part 1: connecting the dots between pathophysiologic mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. J Clinical Aesthet Dermatol. 2012 (in press).
  44. Del Rosso JQ. Advances in understanding and managing rosacea part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea. J Clinical Aesthet Dermatol. 2012 (in press).
  45. Fowler J, Jarratt M, Moore A, et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment of moderate to severe facial erythema of rosacea: results of two multicenter, randomized and vehicle-controlled studies Br J Dermatol. 2011 Nov 2. doi: 10.1111/j.1365-2133.2011.10716.x. [Epub ahead of print].
  46. Shanler SD, Ondo AL. Successful treatment of erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor antagonist, oxymetazoline. Arch Dermatol. 2007;143:1369-1371.
  47. Miyachi Y. Potential antioxidant mechanism of action for metronidazole: implications for rosacea management. Adv Ther. 2001;18:237-243.
  48. Narayanan S, Hünerbein A, Getie M, et al. Scavenging properties of metronidazole on free oxygen radicals in a skin lipid model system. J Pharm Pharmacol. 2007;59:1125-1130.
  49. Akamatsu, H, Oguchi, M, Nishijima S, et al. The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne. Arch. Dermatol Res. 1990;282: 449-454.
  50. Beaufort N, Plaza K, Utzschneider D, et al. Interdependence of kallikrein related pedtidases in proteolytic networks. Biol Chem. 2010;391:581-587.
  51. Akamatsu, H, Komura J, Asada Y, et al. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated disease. Arch Dermatol Res. 1991;283:162-166.
  52. Yamasaki K, Gallo RK et al. Effect of azelaic acid on cathelicidin and serine protease expression. Poster presentation at Fall Clinical Dermatology Conference: October 15-18 2009; Las Vegas, NV.
  53. Sapadin AN, Fleischmajer R. Tetracyclines: non-antibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258-265.
  54. Korting HC, Schollmann C. Tetracycline actions relevant to rosacea treatment. Skin Pharmacol Physiol. 2009;22:287-294.
  55. Webster G, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Clin. 2007;25:122-135.
  56. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple nonantimicrobial mecahanisms. Adv Derm Res. 1998;12:12-26.
  57. Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol. 2008;7:573-576.

Address for Correspondence

James Q. Del Rosso DO FAOCD880 Seven Hills Drive Suite 260 Henderson, Nevada 89052 jqdelrosso@yahoo.com
Close Menu